Current situation of screening for cancer

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 189-198

  Boyle, P ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ECHOMAMMOGRAPHY; FEASIBILITY STUDY; HEALTH PROGRAM; HUMAN; LUNG CANCER; MEDICAL ASSESSMENT; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; METHODOLOGY; OUTCOMES RESEARCH; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; RANDOMIZATION; SAMPLE SIZE; SCREENING TEST; THORAX RADIOGRAPHY; TREATMENT PLANNING; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

EID: 0036435861     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf659     Document Type: Article

References (70)

1. Morrison AS. Screening in Chronic Disease. New York: Oxford University Press 1985.
2. Wilson JMG, Jungner G. Principles and practice of screening for Disease. World Health Organisation Public Health Paper No. 34. Geneva: WHO 1968.
3. National Institutes of Health. Cervical cancer. NIH Consensus Statement. Bethesda, MD: NIH 1996; April 1-3; 43: 1-26.
4. Miller AB. Issues in screening for prostate cancer. In Miller AB, Chamberlain J, Day NE et al. (eds): Cancer Screening. Cambridge: Cambridge University Press 1991.
5. Fahs MC, Mandelblatt J, Schechter C, Muller C. Cost effectiveness of cervical cancer screening in the elderly. Ann Intern Med 1992; 117: 520-527.
6. Hakama M, Magnus K, Petterson F et al. Effect of organised screening on the risk of cervix cancer in the Nordic countries. In Miller AB, Chamberlain J, Day NE et al. (eds): Cancer Screening. Geneva: International Union Against Cancer. Cambridge, UK: CUP 1991.
7. Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. J Am Med Acad 1989; 261: 737-743.
8. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996; 73: 1001-1005.
9. Coibion M, Autier P, Vandam P et al. Is there a role for cervicography in the detection of the pre-malignant lesions of the cervix uteri? Br J Cancer 1994; 70: 125-128.
10. Coppleson M, Reid BL, Skladnev VN, Dalrymple JC. An electronic approach to the detection of pre-cancer and cancer of the uterine cervix: a preliminary evaluation of Polarprobe. Int J Gynecol Cancer 1994; 4: 79-83.
11. Parkin DM, Ferlay J, Pisani P. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
12. Cuzick J, Szarewski A, Terry G et al. Human papillomavirus testing in primary cervical screening. Lancet 1995; 345: 1533-1536.
13. Meijer CJ, van den Brulle AJ, Snijders PJ et al. (eds). The Epidemiology of Cervical Cancer and Human Papillomavirus, IARC Scientific Publications No. 119. Lyon: IARC 1992; 271-281.
14. Department of Health. Health of the Nation. London: Her Majesty's Stationary Office 1993.
15. Wald NJ, Chamberlain J, Hackshaw A et al. Report of the European Society of Mastology (EUSOMA) Breast Cancer Screening Evaluation Committee. Breast 1993; 2: 209-216.
16. Chen HH, Duffy SW, Tabar L, Day NE. Markov chain models for progression of breast cancer. Part I: tumour attributes and the preclinical screen-detectable phase. J Epi Bio 1997; 2: 25-36.
17. Chen HH, Duffy SW, Tabar L, Day NE. Markov chain models for progression of breast cancer. Part II: tumour attributes and the preclinical screen-detectable phase. J Epi Bio 1997: 2: 37-44.
18. Swedish Cancer Society and the Swedish National Board of Health and Welfare. Breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996; 68: 693-699.
19. News and comments. The breast-screening brawl. Science 1997; 275: 1056-1059.
20. Thomas DB, Gao DL, Self SG et al. Randomized trial of breast examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst. 1997; 89: 355-365.
21. Semiglazov VF, Sagaidak VN, Moiseyenko VM, Mikhailov EA. Study of the role of breast self-examination in the reduction of mortality from breast cancer. The Russian Federation/World Health Organisation Study. Eur J Cancer 1993; 29: 2039-2046.
22. Boyle P, Veronesi U, Tubiana M et al. European School of Oncology Advisory Report to the European Commission for the Europe Against Cancer Programme: European Code Against Cancer. Eur J Cancer 1995; 9: 1395-1405.
23. Forrest P. Breast Cancer Screening. London: Her Majesty's Stationary Office 1986.
24. McCann J, Duffy S, Day NE. Predicted long-term mortality reduction associated with the second round of breast screening in East Anglia. Br J Cancer 2001; 84: 423-428.
25. Gotszche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355: 129-134.
26. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001; 358: 1340-1342.
27. Nystrom L, Andersson I, Bjurstam N et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 909-919.
28. Parkin DM, Whelan S, Ferlay et al. (eds): Cancer Incidence in Five Continents, Vol. VII. Lyon: IARC 1997.
29. Morson BC. Gastrointestinal Pathology. Oxford: Blackwell 1979.
30. Boyle P. Progress in preventing death from colorectal cancer (Editorial). Br J Cancer 1995; 72: 528-530.
31. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 major cancers in 1990. Int J Cancer 1999; 83: 18-29.
32. Winawer SJ. A quarter century of colorectal cancer screening: progress and prospects. J Clin Oncol 2001; 18S: 6S-12S.
33. Greegor DH. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA 1967; 201: 123-125.
34. Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
35. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-1371.
36. Kronberg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471.
37. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477.
38. Towler B, Irwig L, Glasziou P et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemocult. BMJ 1998; 317: 559-565.
39. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-1607.
40. Canadian Task Force on Preventive Health Care. Colorectal cancer screening. Can Med Assoc J 2001; 165: 206-207.
41. Advisory Committee on Cancer Prevention. Recommendations on Cancer Screening in the European Union. Eur J Cancer 2000; 36: 1473-1478.
42. Coeberg JWW. Challenges and pitfalls of mass-screening in the European Union. Eur J Cancer 2000; 36: 1469-1472.
43. Autier P, Bleiberg H. Should there be mass screening using faecal occult blood tests for colorectal cancer. Eur J Cancer 1998; 34: 773-780.
44. Lieberman DA, Harford WV, Ahnen et al. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-560.
45. Detsky A. Screening for colon cancer: can we afford colonoscopy? N Engl J Med 2001; 345: 607-608.
46. Selby JV, Friedman GD, Quesenbery CP et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653-657.
47. Greenberg R, Baron J. Prospects for preventing colorectal cancer death. J Natl Cancer Inst 1993; 85: 1182-1184.
48. Boyle P. Progress in preventing death from colorectal cancer (Editorial). Br J Cancer 1995; 72: 528-530.
49. Boyle P. FOBT as screening for colorectal cancer: the current controversy. Ann Oncol 2002; 13: 16-18.
50. Mandel J. Colon and rectal cancer. In Reintgen DS and Clark RA (eds): Cancer Screening. St Louis, MA: Mosby 1996; 55-96.
51. La Vecchia C. Faecal occult blood screening for colorectal cancer: open issues. Ann Oncol 2002; 13: 31-34.
52. McArdle CS. Faecal occult blood testing for colorectal cancer. Ann Oncol 2002; 13: 35-39.
53. Lowenfels AB. Fecal occult blood testing as a screening procedure for colorectal cancer. Ann Oncol 2002; 13: 40-43.
54. Bleiberg H. Hemoccult should no more be used for the screening of colorectal cancer. Ann Oncol 2002; 13: 44-46.
55. Crespi M, Lisi D. Is colorectal cancer screening by faecal occult blood feasible? Ann Oncol 2002; 13: 47-50.
56. Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. Ann Oncol 2002; 13: 51-56.
57. Autier P. Should there be organised faecal-occult-blood test screening established? Ann Oncol 2002; 13: 57-60.
58. Barry MJ. Fecal occult blood testing for colorectal cancer: a perspective. Ann Oncol 2002; 13: 61-64.
59. Chamberlain J, Moss S. (eds). Evaluation of Cancer Screening. Berlin: Springer 1996.
60. Reintgen DS, Clark RA (eds). Cancer Screening. St Louis, MA: Mosby 1996.
61. Catalona WJ. Prostate cancer. In Reintgen DS and Clark RA (eds): Cancer Screening. St Louis, MA: Mosby 1996; 97-117.
62. Chamberlain J, Melia J. In Chamberlain J and Moss S. (eds): Evaluation of Cancer Screening. Berlin: Springer 1996; 117-136.
63. Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA 1996; 276: 1976-1979.
64. Bartsch G, Horninger W, Klocker H et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-424.
65. Strauss G, Dominioni L. International Conference on Prevention and Early Diagnosis of Lung Cancer. Varese Meeting Report. Lung Cancer 1999; 23: 171-172.
66. Marcus PM, Bergstralh EJ, Fagerstrom RM et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000; 92: 1308-1316.
67. Henschke CI, McCauley DI, Yankelevitz DF et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
68. Henschke CI, Naidich DP, Yankelevitz DF et al. Early Lung Cancer Action Project: initial findings on repeat screening. Cancer 2001; 92: 153-159.
69. Kaneko M, Kusumoto M, Kobayashi T et al. Computed tomography screening for lung carcinoma in Japan. Cancer 2000; 89: 2485-2488.
70. Gould MK, Maclean CC, Kuschner WG et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. A meta-analysis. JAMA 2001; 285: 914-924.